摘要
目的:对比培美曲塞与多西他赛联合顺铂治疗晚期非小细胞肺癌(NSCLC)的近期疗效和毒副作用。方法:将48例NSCLC患者随机分为观察组(n=25)和对照组(n=23)。观察组给予培美曲塞联合顺铂治疗,对照组给予多西他赛联合顺铂治疗,21d为1个周期,2个周期后评价疗效,每个周期进行1次毒副作用评价。结果:观察组与对照组客观有效率(ORR)、疾病控制率(DCR)、无进展生存期(PFS)分别为36.0%(9/25)和30.4%(7/23)、84.0%(21/25)和84.0%(18/23)、9.3和8.9个月,两组比较差异无统计学意义,χ2值分别为0.167、0.159和1.576,P值分别为0.683、0.611和0.209。但观察组中性粒细胞减少及脱发的发生率显著低于对照组,分别为28.0%和56.5%、28.0%和60.9%,差异有统计学意义,χ2值分别为4.009和5.259,P值分别为0.045和0.022。结论:培美曲塞联合顺铂与多西他赛联合顺铂的近期疗效相当,但前者毒副作用较后者轻,提高了化疗耐受性,适合临床进一步推广应用。
OBJECTIVE: To compare the short-term effect and toxicity reactions between pemetrexed and docetaxel plus cisplatin for advanced non-small cell lung cancer(NSCLC). METHODS: Forty eight patients of NSCLC were divided into two groups. The observation group (n= 25) received pemetrexed plus cisplatin, and the control group (n= 23) received docetaxel plus cisplatin. Twenty-one days were acted as one course. The effect was evaluated after two courses, and the toxicity reactions were e- valuated every course. RESULTS: The ORR, DCR and PFS in the two groups were respectively 36.0% vs 30.4%, 84.0% vs 84.0 %, 9.3 months vs 8.9 months, with no significant difference (X2 were 0. 167,0. 159 and 1. 576 respectively), P were 0. 683, 0. 611 and 0. 209 respectively. But the rates of neutropenia and alopecia in observation group were obviously lower than that in control group(28.0% vs 56.5% ,28.0% vs 60.9% ,X2 were 4. 009 and 5. 259,P were 0. 045 and 0. 022 respectively). CONCLU- SION: Pemetrexed and docetaxel plus cisplatin on NSCLC have similar short-term effects, but toxicity reactions in the former are slighter than that in the latter. It can increase the tolerance and is appropriate to be popularized more.
出处
《中华肿瘤防治杂志》
CAS
北大核心
2012年第24期1889-1891,共3页
Chinese Journal of Cancer Prevention and Treatment
关键词
癌
非小细胞肺
培美曲塞
药物疗法
多西他赛
药物疗法
抗肿瘤联合化疗方案
carcinoma, non-small cell lung
pemetrexed/drug therapy
doeetaxel/drug therapy
antineplastic corn- bined chemotherapy protocols